The field of cancer immunotherapy has evolved dramatically in recent years. As increasingly greater options for, and combinations of, cancer immunotherapy become available, clinicians need to stay up-to-date on the role of immunotherapy in a rapidly changing therapeutic landscape.

Although there is general agreement on the importance and benefits of early integration of palliative care in oncology, timely and seamless integration remains a major challenge.

Immunotherapy-related toxicity impacts the majority of patients receiving cancer immunotherapy, and a significant proportion of patients experience higher-grade immune-related adverse events (irAEs).

With the improved effectiveness of cancer treatment, more and more patients are surviving longer and may experience fractures as a long-term complication of bone loss.

Despite the high rate of complete remission for patients with ALL, a majority of patients will develop relapsed or refractory disease. Recent advances expanding available therapeutic options could change the standard of care for these patients.